人民财讯5月20日电,三生制药5月20日公告称,公司与辉瑞就PD-1/VEGF双特异性抗体SSGJ-707订立许可协议,辉瑞将获得该产品在全球(不包括中国内地)的独家开发及商业化权利。公司将获得1250百万美元首付款及最多4800百万美元的潜在付款,包括开发、监管批准及销售里程碑付款,并收取双位数百分比的特许权使用费。此外,辉瑞可能认购公司价值100百万美元的新股份。许可协议须满足多项先决条件。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.